In ,a recent media release, Lantheus Holdings announced that the US Food and Drug Administration (FDA) had approved the imaging agent known as piflufolastat F 18 Injection (also known as Pylarify® or more commonly just “PyL”) as a PSMA-based PET imaging agent for identification of prostate cancer. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: imaging, PET scan, PyL, Pylarify | 16 Comments »
This is hardly a radical new finding but yet another study has recently shown that we are over-using expensive scanning tests in the work-up of patients diagnosed with low- and intermediate-risk prostate cancer — and under-using these tests in men initially diagnosed with high-risk disease. … READ MORE …
Filed under: Diagnosis, Management, Risk | Tagged: bone scan, CT scan, MRI, necessary, PET scan | 1 Comment »
A few days ago we suggested that the role of positron emission tomography (PET scanning) as a diagnostic and prognostic tool in patients with prostate cancer was probably best limited to research studies at major medical centers at the present time. A recent study from Germany appears to confirm this suggestion. … READ MORE …
Filed under: Diagnosis, Management, Risk | Tagged: lymph nodes, PET scan, positron emission tomography | 3 Comments »
Today we cover reports on:
Filed under: Diagnosis, Drugs in development, Management, Risk, Treatment, Uncategorized | Tagged: ARTS, chemotherapy, dutasteride, HIV, incidence, PET scan | Leave a comment »
